Survey: Illumina, SOLiD, and 454 Gain Ground in Research Labs; Most Users Mull Additional Purchases | GenomeWeb

By Julia Karow

As second-generation sequencing platforms have matured, all three major high-throughput sequencing systems — Illumina's Genome Analyzer, Life Technologies' ABI SOLiD, and Roche's 454 GS FLX — have entered labs across the world, according to a recent survey by In Sequence.

Although two-thirds of the 50 labs polled in the survey own only a single type of next-gen sequencing platform, a number of centers have started to mix and match systems from different vendors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.